Fc Domain Biomimetics for IVIG Sterility and Allergy Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current intravenous immunoglobulin (IVIG) products face challenges such as inadequate sterility, presence of impurities, variability in lot-to-lot composition, and potential allergic reactions due to immunoglobulin A content, limiting their effectiveness in treating autoimmune and inflammatory diseases.
Innovation Solution
Development of biologically active biomimetic molecules comprising stabilized functional portions of IgG Fc fragments that specifically bind to Fcγ receptors, including serial stradomers, core stradomers, and stradobodies, which mimic the immunomodulatory effects of IVIG without the limitations of traditional IVIG formulations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional IVIG products are used, then immune deficiency and autoimmune diseases can be treated, but sterility issues, impurities, lot-to-lot variability, and allergic reactions occur
Solution Approach 1:
The patent extracts and isolates the functional Fc domain from complete IgG molecules to create purified Fc fragments. This extraction process removes harmful components (IgA, impurities, variable regions) while retaining the therapeutic Fc-mediated immunomodulatory activity, thereby treating autoimmune diseases without the harmful effects of traditional IVIG products
Solution Approach 2:
The patent creates Fc fragments with specific local properties by isolating only the constant region domains (CH2-CH3) that mediate FcγR binding. This localized purification provides consistent, predictable immunomodulatory activity without the variability and harmful components present in whole IVIG products
2Reliability
If hIVIG formulations are used, then autoimmune diseases can be treated, but IgA content causes allergic and anaphylactic reactions
Solution Approach 1:
The patent extracts only the Fc domain from complete IgG molecules through proteolytic cleavage, thereby removing IgA and other allergenic components present in traditional hIVIG formulations. The resulting purified Fc fragments provide therapeutic benefit without triggering allergic or anaphylactic reactions in IgA-deficient recipients
3Reliability
If traditional IVIG products are used, then immune-mediated diseases can be treated, but lot-to-lot variation in composition occurs
Solution Approach 1:
The patent produces Fc fragments with standardized, defined composition by isolating only the constant region domains through controlled proteolytic cleavage. This localized purification approach eliminates the lot-to-lot variability inherent in pooled plasma-derived IVIG products, providing consistent FcγR binding activity and predictable therapeutic outcomes across all batches
4Manufacturing precision
If Fc fragments are used instead of whole IVIG, then specificity and stability improve, but manufacturing complexity increases
Solution Approach 1:
The patent segments the IgG molecule into distinct functional parts (Fab and Fc domains) through proteolytic cleavage. This segmentation allows isolation of the therapeutically active Fc domain with defined structure and function, improving manufacturing precision and specificity while enabling standardized production through controlled enzymatic processing
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These biomimetic molecules effectively treat and prevent autoimmune and inflammatory disorders by modulating the immune response, overcoming the limitations of traditional IVIG products and providing a more stable and targeted therapeutic approach.
Implementation Method 1
comprising two associated Fc domain monomers
Data Source
AI summary
IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacement compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.